Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación
Artículo científico (JournalArticle)
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets
Many cancer patients do not benefit from PD-L1/PD-1 blockade immunotherapies. PD-1 and LAG-3 co-upregulation in T-cells is one of the major mechanisms of resistance by establishing a highly dysfunctional state in T-cells. To identify shared features associated to PD-1/LAG-3 dysfunctionality in human cancers and T-cells, multiomic expression profiles were obtained for all TCGA cancers immune infiltrates. A PD-1/LAG-3 dysfunctional signature was found which regulated immune, metabolic, genetic, and epigenetic pathways, but especially a reinforced negative regulation of the TCR signalosome. These results were validated in T-cell lines with constitutively active PD-1, LAG-3 pathways and their combination. A differential analysis of the proteome of PD-1/LAG-3 T-cells showed a specific enrichment in ubiquitin ligases participating in E3 ubiquitination pathways. PD-1/LAG-3 co-blockade inhibited CBL-B expression, while the use of a bispecific drug in clinical development also repressed C-CBL expression, which reverted T-cell dysfunctionality in lung cancer patients resistant to PD-L1/PD-1 blockade. The combination of CBL-B-specific small molecule inhibitors with anti-PD-1/anti-LAG-3 immunotherapies demonstrated notable therapeutic efficacy in models of lung cancer refractory to immunotherapies, overcoming PD-1/LAG-3 mediated resistance. © The Author(s) 2024., This research was supported by: The Spanish Association against Cancer (AECC), PROYE16001ESCO; Instituto de Salud Carlos III (ISCIII)-FEDER Project grants FIS PI20/00010, FIS PI23/00196, COV20/00237, and TRANSPOCART ICI19/00069; Biomedicine Project Grant from the Department of Health of the Government of Navarre-FEDER funds (BMED 050-2019, 51-2021, 036-2023); Strategic projects from the Department of Industry, Government of Navarre (AGATA, Ref. 0011-1411-2020-000013; LINTERNA, Ref. 0011-1411-2020-000033; DESCARTHES, 0011-1411-2019-000058); European Union Horizon 2020 ISOLDA project, under grant agreement ID: 848166. LC is financed byInstituto de Salud Carlos III (ISCIII), co-financed by FEDER funds, "ContratosPFIS: contratos predoctorales de formación en investigación en salud" (FI21/00080); ME is financed by the Navarrabiomed-Fundación Miguel Servetpredoctoral contract.
Proyecto:
European Commission / Horizon 2020 Framework Programme 848166
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI20-00010
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI23-00196
,
ISCIII COV20-00237
,
ISCIII ICI19-00069
,
Gobierno de Navarra 050-2019
,
Gobierno de Navarra 51-2021
,
Gobierno de Navarra 036-2023
,
Gobierno de Navarra 0011-1411-2020-000013
,
Gobierno de Navarra 0011-1411-2020-000033
,
Gobierno de Navarra 0011-1411-2019-000058